<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="361f79e5-0981-c4de-e063-6394a90a39ac"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Sodium Polystyrene Sulfonate Powder
 <br/>
      <br/>
These highlights do not include all the information needed to use Sodium Polystyrene Sulfonate Powder, for Suspension safely and effectively. See full prescribing information for Sodium Polystyrene Sulfonate Powder, for Suspension.
 <br/>
Sodium Polystyrene Sulfonate Powder, for Suspension, for oral or rectal use
 <br/>
Initial U.S. Approval: 1958
</title>
   <effectiveTime value="20250527"/>
   <setId root="2d95d23e-94c8-4975-99f5-ce746dfbb60e"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="047437707"/>
            <name>ATLANTIC BIOLOGICALS CORP.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="361f8c31-2196-d286-e063-6394a90af6b2"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250527"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="17856-0024" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Sodium Polystyrene Sulfonate</name>
                        <formCode code="C42975" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, FOR SUSPENSION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Sodium Polystyrene Sulfonate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="42806-013" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="meq" value="4.1"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1699G8679Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM POLYSTYRENE SULFONATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="70KO0R01RY" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSTYRENE SULFONIC ACID</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43187" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CUP"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="50" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="17856-0024-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43179" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX, UNIT-DOSE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230411"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43187" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CUP"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="50" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="17856-0024-2" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43179" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX, UNIT-DOSE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230411"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA202333" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20140414"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_cec05f75-7853-4090-a3cd-b644fc5065d2">
               <id root="361f79e5-0982-c4de-e063-6394a90a39ac"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Limitation of Use:</content>
                  </paragraph>
                  <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action
 
  <content styleCode="italics">
                        <linkHtml href="#ID_3888401f-cd26-4979-94ce-136469544e3a">[see Clinical Pharmacology (12.2)]</linkHtml>
                     </content>.

 </paragraph>
               </text>
               <effectiveTime value="20230411"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia
 
    <linkHtml href="#ID_cec05f75-7853-4090-a3cd-b644fc5065d2">(1)</linkHtml>.

   </paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitation of Use:</content>
                        </paragraph>
                        <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action
 
    <linkHtml href="#ID_cec05f75-7853-4090-a3cd-b644fc5065d2">(1)</linkHtml>.

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_ffa60766-2bc4-4d55-a6d0-ce1f8e6bf782">
               <id root="361f79e5-0983-c4de-e063-6394a90a39ac"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20230411"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Oral</content>: The average total daily adult dose of Sodium Polystyrene Sulfonate Powder, for Suspension is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily (
 
    <linkHtml href="#ID_070959cf-4dcb-4864-b665-a15bced199c3">2.1</linkHtml>).

   </paragraph>
                        <paragraph>
                           <content styleCode="underline">Rectal</content>: The average adult dose is 30 g to 50 g every six hours (
 
    <linkHtml href="#ID_070959cf-4dcb-4864-b665-a15bced199c3">2.1</linkHtml>).

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_070959cf-4dcb-4864-b665-a15bced199c3">
                     <id root="361f79e5-0984-c4de-e063-6394a90a39ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 General Information</title>
                     <text>
                        <paragraph>Administer Sodium Polystyrene Sulfonate Powder, for Suspension at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation
 
  <content styleCode="italics">[
  
   <linkHtml href="#ID_867632e1-9b03-4dd0-8d11-5157119de3a3">see Warnings and Precautions (5.5)</linkHtml>and
 
  </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_4d75ac20-8b41-4428-855e-6d70d889eb7d">Drug Interaction (7)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_62a5f4e1-775c-4204-a3cb-ccc42948e0ab">
                     <id root="361f79e5-0985-c4de-e063-6394a90a39ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage</title>
                     <text>
                        <paragraph>The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Oral</content>
                        </paragraph>
                        <paragraph>The average total daily adult dose of Sodium Polystyrene Sulfonate Powder, for Suspension is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Rectal</content>
                        </paragraph>
                        <paragraph>The average adult dose is 30 g to 50 g every six hours.</paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b7656f20-e428-44ca-9c56-f191eb384fa8">
                     <id root="361f79e5-0986-c4de-e063-6394a90a39ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Preparation and Administration</title>
                     <text>
                        <paragraph>Prepare suspension fresh and use within 24 hours.</paragraph>
                        <paragraph>Do not heat Sodium Polystyrene Sulfonate Powder, for Suspension as it could alter the exchange properties of the resin.</paragraph>
                        <paragraph>One level teaspoon contains approximately 3.5 g of Sodium Polystyrene Sulfonate Powder, for Suspension and 15 mEq of sodium.</paragraph>
                        <paragraph>Oral Suspension</paragraph>
                        <paragraph>Suspend each dose in a small quantity of water or syrup, approximately 3 to 4 mL of liquid per gram of resin. Administer with patient in an upright position [SEE WARNINGS AND PRECAUTIONS (5.4)].</paragraph>
                        <paragraph>Enema</paragraph>
                        <paragraph>After an initial cleansing enema, insert a soft, large size (French 28) rubber tube into the rectum for a distance of about 20 cm, with the tip well into the sigmoid colon, and tape in place.</paragraph>
                        <paragraph>Administer as a warm (body temperature) emulsion in 100 mL of aqueous vehicle and flush with 50 to 100 ml of fluid. A somewhat thicker suspension may be used, but do not form a paste.</paragraph>
                        <paragraph>Agitate the emulsion gently during administration. The resin should be retained for as long as possible and follow by a cleansing enema with a nonsodium containing solution. Ensure an adequate volume of cleansing solution (up to 2 liters) is utilized.</paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_c3c348b2-bb4c-40e1-9cfa-b07d28fbc977">
               <id root="361f79e5-0987-c4de-e063-6394a90a39ac"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension is a cream to light brown, finely ground powder and is available in 453.6 g jars and 15 g bottles</paragraph>
               </text>
               <effectiveTime value="20230411"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension is available as a cream to light brown, finely ground powder
 
    <linkHtml href="#ID_c3c348b2-bb4c-40e1-9cfa-b07d28fbc977">(3)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_e72cc2f6-f4c5-43c1-adee-7a8d9a81661a">
               <id root="361f79e5-0988-c4de-e063-6394a90a39ac"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension is contraindicated in patients with the following conditions:</paragraph>
                  <paragraph>•Hypersensitivity to polystyrene sulfonate resins 
  <br/>  •Obstructive bowel disease 
  <br/>  •Neonates with reduced gut motility
 </paragraph>
               </text>
               <effectiveTime value="20230411"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>•Hypersensitivity to polystyrene sulfonate resins (4)•Obstructive bowel disease (4)•Neonates with reduced gut motility (4)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_33d8fa6a-ca41-4900-9afa-4bcc7683f9a4">
               <id root="361f79e5-0989-c4de-e063-6394a90a39ac"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20230412"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>•Intestinal Necrosis: cases of intestinal necrosis and other serious gastrointestinal events have been reported (5.1).</item>
                           <item>•Electrolyte Disturbances: Severe hypokalemia can occur. (5.2).</item>
                           <item>•Fluid overload in patient sensitive to high sodium intake: Monitor patients who are sensitive to sodium intake for signs of fluid overload. (5.3).</item>
                           <item>•Risk of aspiration: Acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles has been reported. (5.4)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_29fc01ac-980a-43bc-87a1-01602c48940d">
                     <id root="361f79e5-098a-c4de-e063-6394a90a39ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Intestinal Necrosis</title>
                     <text>
                        <paragraph>Cases of intestinal necrosis, some fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with Sodium Polystyrene Sulfonate Powder, for Suspension use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency and failure. Concomitant administration of sorbitol is not recommended.</paragraph>
                        <paragraph>•Use only in patients who have normal bowel function. Avoid use in patients who have not had a bowel movement post-surgery. 
  <br/>  •Avoid use in patients who are at risk for developing constipation or impaction (including those with history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction).
 </paragraph>
                        <paragraph>Discontinue use in patients who develop constipation.</paragraph>
                     </text>
                     <effectiveTime value="20230412"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2c9c4a80-5975-4e27-8e12-d1738ce6c2ab">
                     <id root="361f79e5-098b-c4de-e063-6394a90a39ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Electrolyte Disturbances</title>
                     <text>
                        <paragraph>Monitor serum potassium during therapy because severe hypokalemia may occur.</paragraph>
                        <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension is not totally selective for potassium, and small amounts of other cations such as magnesium and calcium can also be lost during treatment. Monitor calcium and magnesium in patients receiving Sodium Polystyrene Sulfonate Powder, for Suspension.</paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b357e8ac-6915-488a-8d84-24e76aca1d6d">
                     <id root="361f79e5-098c-c4de-e063-6394a90a39ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Fluid Overload in Patients Sensitive to High Sodium Intake</title>
                     <text>
                        <paragraph>Each 15 g dose of Sodium Polystyrene Sulfonate Powder, for Suspension contains 1500 mg (60 mEq) of sodium. Monitor patients who are sensitive to sodium intake (heart failure, hypertension, edema) for signs of fluid overload. Adjustment of other sources of sodium may be required.</paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_71b28417-f5d9-4b24-948a-9265f0d6aca8">
                     <id root="361f79e5-098d-c4de-e063-6394a90a39ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Risk of Aspiration</title>
                     <text>
                        <paragraph>Cases of acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles have been reported. Patients with impaired gag reflex, altered level of consciousness, or patients prone to regurgitation may be at increased risk. Administer Sodium Polystyrene Sulfonate Powder, for Suspension with the patient in an upright position.</paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_867632e1-9b03-4dd0-8d11-5157119de3a3">
                     <id root="361f79e5-098e-c4de-e063-6394a90a39ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Binding to Other Orally Administered Medications</title>
                     <text>
                        <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension may bind orally administered medications, which could decrease their gastrointestinal absorption and lead to reduced efficacy. Administer other oral medications at least 3 hours before or 3 hours after Sodium Polystyrene Sulfonate Powder, for Suspension. Patients with gastroparesis may require a 6 hour separation. [SEE DOSAGE AND ADMINISTRATION (2.1) and DRUG INTERACTIONS (7)].</paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_0f79f00c-ee51-4c36-8158-3e21f60015f7">
               <id root="361f79e5-098f-c4de-e063-6394a90a39ac"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Intestinal Necrosis
  
   <content styleCode="italics">[
   
    <linkHtml href="#_5.1_Intestinal_Necrosis">see Warnings and Precautions (5.1)</linkHtml>]
  
   </content>
                     </item>
                     <item>Electrolyte Disturbances
  
   <content styleCode="italics">[see
   
    <linkHtml href="#ID_2c9c4a80-5975-4e27-8e12-d1738ce6c2ab">Warnings and Precautions (5.2,</linkHtml>
                           <linkHtml href="#ID_b357e8ac-6915-488a-8d84-24e76aca1d6d">5.3)</linkHtml>]
  
   </content>
                     </item>
                     <item>Aspiration
  
   <content styleCode="italics">[
   
    <linkHtml href="#ID_71b28417-f5d9-4b24-948a-9265f0d6aca8">see Warnings and Precautions (5.4)</linkHtml>]
  
   </content>
                     </item>
                  </list>
                  <paragraph>The following adverse reactions have been identified during post-approval use of Sodium Polystyrene Sulfonate Powder, for Suspension. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal:</content>anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, ulcerations, vomiting, gastric irritation, intestinal obstruction (due to concentration of aluminium hydroxide)

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Metabolic:</content>systemic alkalosis

 </paragraph>
               </text>
               <effectiveTime value="20230411"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse reactions reported include: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, vomiting
 
    <linkHtml href="#ID_0f79f00c-ee51-4c36-8158-3e21f60015f7">(6)</linkHtml>.

   </paragraph>
                        <paragraph>To report SUSPECTED ADVERSE REACTIONS, contact Epic Pharma, LLC 1-888-374-2791 or FDA at 1-800-FDA-1088 or
 
    <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_4d75ac20-8b41-4428-855e-6d70d889eb7d">
               <id root="361f79e5-0990-c4de-e063-6394a90a39ac"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20230411"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Take other orally administered drugs at least 3 hours before or 3 hours after Sodium Polystyrene Sulfonate Powder, for Suspension (
  
     <linkHtml href="#ID_db6acc49-56ae-4d74-9386-06e879cf6c17">7.1</linkHtml>).
 
    </item>
                           <item>Cation-Donating Antacids: may reduce the resin’s potassium exchange capability and increase risk of systemic alkalosis (
  
     <linkHtml href="#ID_9a3a7dee-4263-4278-9ee9-f90be5863e04">7.2</linkHtml>).
 
    </item>
                           <item>Sorbitol: Concomitant use may contribute to the risk of intestinal necrosis and is not recommended (
  
     <linkHtml href="#ID_31b9208c-de79-457e-8fd7-59f7fca18fb6">7.3</linkHtml>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_db6acc49-56ae-4d74-9386-06e879cf6c17">
                     <id root="361f79e5-0991-c4de-e063-6394a90a39ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 General Interactions</title>
                     <text>
                        <paragraph>No formal drug interaction studies have been conducted in humans.</paragraph>
                        <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension has the potential to bind other drugs. In in vitro binding studies, Sodium Polystyrene Sulfonate Powder, for Suspension was shown to significantly bind the oral medications (n=6) that were tested. Decreased absorption of lithium and thyroxine have also been reported with co-administration of Sodium Polystyrene Sulfonate Powder, for Suspension. Binding of Sodium Polystyrene Sulfonate Powder, for Suspension to other oral medications could cause decreased gastrointestinal absorption and loss of efficacy when taken close to the time Sodium Polystyrene Sulfonate Powder, for Suspension is administered. Administer Sodium Polystyrene Sulfonate Powder, for Suspension at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation. Monitor for clinical response and/or blood levels where possible.</paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9a3a7dee-4263-4278-9ee9-f90be5863e04">
                     <id root="361f79e5-0992-c4de-e063-6394a90a39ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Cation-Donating Antacids</title>
                     <text>
                        <paragraph>The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis</paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_31b9208c-de79-457e-8fd7-59f7fca18fb6">
                     <id root="361f79e5-0993-c4de-e063-6394a90a39ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Sorbitol</title>
                     <text>
                        <paragraph>Sorbitol may contribute to the risk of intestinal necrosis
 
  <content styleCode="italics">[
  
   <linkHtml href="#_5.1_Intestinal_Necrosis">see Warnings and Precautions (5.1)</linkHtml>]
 
  </content>and concomitant use is not recommended.

 </paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8a75d545-4030-4a07-8fda-3a1a3c8d3bf2">
               <id root="361f79e5-0994-c4de-e063-6394a90a39ac"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20230411"/>
               <component>
                  <section ID="ID_71b28e7b-89fb-4334-8d4d-96d5bbbdb1f0">
                     <id root="361f79e5-0995-c4de-e063-6394a90a39ac"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk.</paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3b1e4c8f-5614-497a-a759-cee90390c67e">
                     <id root="361f79e5-0996-c4de-e063-6394a90a39ac"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Labor and Delivery</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant.</paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c2d29822-8d51-4285-952f-e0b7c5df2a70">
                     <id root="361f79e5-0997-c4de-e063-6394a90a39ac"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Studies of safety and efficacy have not been conducted in pediatric patients.</paragraph>
                        <paragraph>In pediatric patients, as in adults, Sodium Polystyrene Sulfonate Powder, for Suspension is expected to bind potassium at the practical exchange ratio of 1mEq potassium per 1 gram of resin.</paragraph>
                        <paragraph>In neonates, Sodium Polystyrene Sulfonate Powder, for Suspension should not be given by the oral route. In both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. Premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with Sodium Polystyrene Sulfonate Powder, for Suspension use
 
  <content styleCode="italics">[
  
   <linkHtml href="#ID_71b28417-f5d9-4b24-948a-9265f0d6aca8">see Warnings and Precautions (5.4)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7478ff2e-6129-4185-8821-9830c406a404">
               <id root="361f79e5-0998-c4de-e063-6394a90a39ac"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Overdosage may result in electrolyte disturbances including hypokalemia, hypocalcemia, and hypomagnesemia. Appropriate measures should be taken to correct serum electrolytes (potassium, calcium, magnesium), and the resin should be removed from the alimentary tract by appropriate use of laxatives or enemas.</paragraph>
               </text>
               <effectiveTime value="20230411"/>
            </section>
         </component>
         <component>
            <section ID="ID_a43153cb-f4e2-49c8-93d7-2fd6ed58ef85">
               <id root="361f79e5-0999-c4de-e063-6394a90a39ac"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension is a benzene, diethenyl-polymer, with ethenylbenzene, sulfonated, sodium salt and has the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L37114880-b874-4b3e-a7ac-e4b9da99b3dc"/>
                  </paragraph>
                  <paragraph>The drug is a cream to light brown finely ground, powdered form of sodium polystyrene sulfonate, a cation-exchange resin prepared in the sodium phase with an in vitro exchange capacity of approximately 3.1 mEq (</paragraph>
                  <paragraph>
                     <content styleCode="italics">in vivo</content>
                  </paragraph>
                  <paragraph>approximately 1 mEq) of potassium per gram. The sodium content is approximately 100 mg (4.1 mEq) per gram of the drug. It can be administered orally or rectally as an enema.</paragraph>
                  <paragraph>One gram of Sodium Polystyrene Sulfonate Powder, for Suspension contains 4.1 mEq of sodium.</paragraph>
               </text>
               <effectiveTime value="20230412"/>
               <component>
                  <observationMedia ID="L37114880-b874-4b3e-a7ac-e4b9da99b3dc">
                     <text>L:\Labeling Department\ANDA\Sodium Polystyrene Sulfonate_SZ- Done\Epic\Package Insert\2017.10 RLD update\Platimun\Docs for Submission\SBS\Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f14f684b-4c45-45ad-9f05-5275f85c1a10">
               <id root="361f79e5-099a-c4de-e063-6394a90a39ac"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20230411"/>
               <component>
                  <section ID="ID_190182be-52b7-4d70-a401-2d8fe6b74ed7">
                     <id root="361f79e5-099b-c4de-e063-6394a90a39ac"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension is a non-absorbed, cation exchange polymer that contains a sodium counterion.</paragraph>
                        <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels. The practical exchange ratio is 1 mEq K per 1 gram of resin.</paragraph>
                        <paragraph>As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. This action occurs primarily in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. The efficiency of this process is limited and unpredictably variable.</paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3888401f-cd26-4979-94ce-136469544e3a">
                     <id root="361f79e5-099c-c4de-e063-6394a90a39ac"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The effective lowering of serum potassium with Sodium Polystyrene Sulfonate Powder, for Suspension may take hours to days.</paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_04c4afe6-00c1-4fcf-9959-58874c3955a0">
                     <id root="361f79e5-099d-c4de-e063-6394a90a39ac"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The
 
  <content styleCode="italics">in vivo</content>efficiency of sodium-potassium exchange resins is approximately 33 percent; hence, about one third of the resin's actual sodium content is delivered to the body.

 </paragraph>
                        <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension is not absorbed systemically.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content>binding studies showed that Sodium Polystyrene Sulfonate Powder, for Suspension bound significantly to the following tested drugs - warfarin, metoprolol, phenytoin, furosemide, amlodipine and amoxicillin.

 </paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7c388ca4-1b7d-4137-a02b-1c7328883d0f">
               <id root="361f79e5-099e-c4de-e063-6394a90a39ac"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20230411"/>
               <component>
                  <section ID="ID_750ab973-46cd-455d-83cd-44866810ac14">
                     <id root="361f79e5-099f-c4de-e063-6394a90a39ac"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Studies have not been performed.</paragraph>
                     </text>
                     <effectiveTime value="20230411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_441ab405-dbdd-47be-8c19-f0005a6bb777">
               <id root="361f79e5-09a0-c4de-e063-6394a90a39ac"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Sodium Polystyrene Sulfonate Powder, for Suspension is available as follows:</paragraph>
                  <paragraph>ndc 17856-0024-01  SODIUM POLYSTYRENE SULFONATE PWD 15 GM CUP 50 ct UD</paragraph>
                  <paragraph>ndc 17856-0024-02  SODIUM POLYSTYRENE SULFONATE PWD 30 GM CUP 50 ct UD</paragraph>
                  <paragraph/>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20230411"/>
            </section>
         </component>
         <component>
            <section ID="ID_d0f64591-ba18-4816-a037-078124bf9b7b">
               <id root="361f79e5-09a1-c4de-e063-6394a90a39ac"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Drug Interactions</content>
                  </paragraph>
                  <paragraph>Advise patients who are taking other oral medication to separate the dosing of Sodium Polystyrene Sulfonate Powder, for Suspension by at least 3 hours (before or after)
 
  <content styleCode="italics">[
  
   <linkHtml href="#ID_070959cf-4dcb-4864-b665-a15bced199c3">see Dosage and Administration (2.1),</linkHtml>
                        <linkHtml href="#ID_867632e1-9b03-4dd0-8d11-5157119de3a3">Warnings and Precautions (5.5),</linkHtml>and
  
   <linkHtml href="#_7.1_General_Interactions">Drug Interactions (7.1)</linkHtml>]
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>DISTRIBUTED BY:</paragraph>
                  <paragraph>ATLANTIC BIOLOGICALS CORP</paragraph>
                  <paragraph>MIAMI FL 33179</paragraph>
               </text>
               <effectiveTime value="20230411"/>
            </section>
         </component>
         <component>
            <section ID="ID_0c062cc8-6757-4a39-b68f-e8cfc70037d8">
               <id root="361f79e5-09a2-c4de-e063-6394a90a39ac"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lfb3bf929-8c08-4bd3-8f9d-2bd7e6f8037a"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lc11acfac-3306-40bf-9f9e-ab58431a8e62"/>
                  </paragraph>
               </text>
               <effectiveTime value="20230412"/>
               <component>
                  <observationMedia ID="Lfb3bf929-8c08-4bd3-8f9d-2bd7e6f8037a">
                     <text>15 GM</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="17856-0024-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lc11acfac-3306-40bf-9f9e-ab58431a8e62">
                     <text>30 GM</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="17856-0024-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>